Volcano Corporation announced its Fractional Flow Reserve (FFR) technology can now integrate with the FFR modules of hemodynamic monitoring systems from GE, Siemens, McKesson, and Mennen. Volcano's Smart MapR Pressure Instrument and PrimeWireR Pressure Guide Wire are now compatible with the majority of hemodynamic monitoring systems, making the benefits of FFR accessible to more clinicians and patients. Volcano's SmartMap will provide a pressure reading to GE Healthcare's Mac-LabR XT and XTi hemodynamic recording systems version 6.8.1, Siemens' AXIOM Sensis XP VC11, McKesson's Horizon CardiologyT Hemo version 12.1, and Mennen's Horizon XVu Hemodynamic Monitoring System. With the pressure measurement derived from Volcano's PrimeWireR hemodynamic monitoring systems have the ability to calculate the FFR gradient and display the FFR measurement on the hemodynamic screen in the cath lab.

Volcano Corporation expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on March 4, 2010).

Volcano Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported net loss of $12,075,000 or $0.25 per diluted share on revenues of $71,014,000 compared to net income of $1,358,000 or $0.03 per diluted share on revenues of $49,253,000 for the same period a year ago. Loss before provision for income taxes was $11,721,000 compared to income before provision for income taxes of $1,271,000 for the same period a year ago. Operating loss was $12,002,000 compared to $18,000 for the same period a year ago. Non-GAAP operating income was $7,034,000 compared to $2,797,000 for the same period a year ago. Non-GAAP net income was $6,961,000 or 0.14 per diluted share compared to $4,173,000 or 0.08 per diluted share for the same period a year ago. For the year ended, the company reported net loss of $28,954,000 or $0.60 per diluted share on revenues of $227,867,000 compared to net loss of $13,705,000 or $0.29 per diluted share on revenues of $171,495,000 for the same period a year ago. Loss before provision for income taxes was $27,767,000 compared to $13,085,000 for the same period a year ago. Operating loss was $30,846,000 compared to $19,663,000 for the same period a year ago. Non-GAAP operating loss was $2,239,000 compared to non-GAAP operating income of $5,433,000 for the same period a year ago. Non-GAAP net loss was $347,000 or 0.01 per diluted share compared to non-GAAP net income of $11,391,000 or 0.23 per diluted share for the same period a year ago. The company provided earnings guidance for fiscal 2010. The company expects non-GAAP net income to be in the range of $15,927,000 or $0.30 per diluted share to $18,535 or 0.35 per diluted share, GAAP net income to be in the range of $2,627,000 to $5,235,000, non-GAAP operating income to be in the range of $17,178,000 to $19,786,000 and GAAP operating income to be in the range of $3,878,000 to $6,486,000 in fiscal 2010. Net interest income for 2010 is expected to be approximately $450,000. On a GAAP basis, the company expects to report net income of $0.05 to $0.10 per diluted share. Based on the expected timing of these investments and the anticipated growth trajectory for revenues, the company expects to be profitable on a GAAP basis beginning in the third quarter of fiscal 2010 and profitable on a GAAP basis for all of fiscal 2010. On a consolidated basis, the company expects total revenues in fiscal 2010 of $277-$282 million, an increase of approximately 22% over revenues in 2009. The expected revenues for 2010 include approximately $20 million in revenues from Axsun Technologies Inc.

CardioSpectra founders win UT System Chancellor’s award for entrepreneurship

Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems

Volcano Announces Activities at the ACC 2010

Volcano Corporation Presentation at Roth Capital Partners Conference to be Webcast

Volcano Reports 44 Percent Increase in Fourth Quarter Revenues

Volcano Corporation Presentation at Roth Capital Partners Conference to be Webcast

Volcano takes bigger loss, but shares gain ground

VOLCANO CORP Files SEC form 10-K, Annual Report

Volcano takes bigger loss, but shares gain ground

Volcano Reports 44 Percent Increase in Fourth Quarter Revenues

Volcano Corporation Fourth Quarter Conference Call, Webcast scheduled for 5:00 pm ET today

VOLCANO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast

Volcano Corporation Announces Litigation Status

Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter

Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter

Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast

VOLCANO CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter

UPDATE - Volcano gets FDA nod to market digital catheter